U
Alumis Inc.
Recommendation
Prev Close
--
Volume
--
Avg Vol (90D)
--
Market Cap
$490.14M
Dividend & Yield
--
52-Week Range
-- - --
P/E (TTM)
--
EPS (TTM)
-$4.53
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
There are no news to display.
Income Statement
Total Revenue (TTM)
$20.06M
EBITDA (TTM)
-$416.04M
EBIT (TTM)
-$419.39M
Net Income (TTM)
-$227.52M
Balance Sheet
Total Assets (Q)
$610.93M
Total Debt (Q)
$38.78M
Total Liabilities (Q)
$125.60M
Book Value Per Share (Q)
$4.66
Cash Flow
Cash from Operations (TTM)
-$345.24M
Cash from Investing (TTM)
$106.59M
Cash from Financing (TTM)
$235.91M
Net Change in Cash (TTM)
-$2.74M
Filings
Filing Date
Wednesday, August 13, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Loading...
Beta
--
7-Day Total Return
--
30-Day Total Return
--
60-Day Total Return
--
90-Day Total Return
--
Year to Date Total Return
--
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
-- - --
52-week High
-- - --
Valuation
Market Cap
$490.14M - Small Cap
Enterprise Value
$42.60M
Price/Sales (TTM)
--
Price/Book (Q)
--
Dividends and Shares
Shares Outstanding
76.64
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.alumis.com
Phone Number
650 231 6625
Address
280 East Grand Avenue
South San Francisco, CA 94080
Country
United States
Year Founded
2021
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company’s clinical asset comprises ESK-001, an... more